Iovance Biotherapeutics, Inc. Stock

Equities

IOVA

US4622601007

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-12 pm EDT 5-day change 1st Jan Change
12.36 USD -6.29% Intraday chart for Iovance Biotherapeutics, Inc. -8.65% +52.03%
Sales 2024 * 161M Sales 2025 * 413M Capitalization 3.45B
Net income 2024 * -352M Net income 2025 * -245M EV / Sales 2024 * 20.6 x
Net cash position 2024 * 133M Net cash position 2025 * 251M EV / Sales 2025 * 7.75 x
P/E ratio 2024 *
-9.51 x
P/E ratio 2025 *
-17.1 x
Employees 557
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.71%
More Fundamentals * Assessed data
Dynamic Chart
General (Ret.) Merrill A. McPeak, Member of the Board of Directors of Iovance Biotherapeutics, Inc. Retires and Not Stands for Re-Election CI
Piper Sandler Adjusts Iovance Biotherapeutics Price Target to $19 From $18, Maintains Overweight Rating MT
Transcript : Iovance Biotherapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:45 AM
Sector Update: Health Care Stocks Lean Lower Pre-Bell Monday MT
Iovance Biotherapeutics Says FDA Lifts Partial Clinical Hold on Lung Cancer Study MT
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145 DJ
Iovance Biotherapeutics Announces Fda Has Lifted Clinical Hold on the Iov-Lun-202 Registrational Trial in Non-Small Cell Lung Cancer CI
Wells Fargo Adjusts Price Target on Iovance Biotherapeutics to $25 From $22, Maintains Overweight Rating MT
Barclays Raises Price Target on Iovance Biotherapeutics to $22 From $18, Maintains Overweight Rating MT
Iovance Biotherapeutics Q4 Loss Narrows, Posts Revenue MT
Transcript : Iovance Biotherapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Earnings Flash (IOVA) IOVANCE BIOTHERAPEUTICS Reports Q4 Revenue $482,000 MT
Iovance Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Iovance Biotherapeutics Insider Bought Shares Worth $45,750,000, According to a Recent SEC Filing MT
Iovance Biotherapeutics Insider Bought Shares Worth $292,800, According to a Recent SEC Filing MT
More news
1 day-6.29%
1 week-8.65%
Current month-16.60%
1 month-16.09%
3 months+37.18%
6 months+240.50%
Current year+52.03%
More quotes
1 week
12.11
Extreme 12.11
13.59
1 month
12.11
Extreme 12.11
15.90
Current year
7.34
Extreme 7.34
18.33
1 year
3.21
Extreme 3.21
18.33
3 years
3.21
Extreme 3.21
33.55
5 years
3.21
Extreme 3.21
54.21
10 years
3.21
Extreme 3.21
54.21
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 16-09-29
Director of Finance/CFO 51 20-12-13
Chief Tech/Sci/R&D Officer - 21-06-30
Members of the board TitleAgeSince
Director/Board Member 88 11-07-19
Director/Board Member 56 16-06-06
Director/Board Member 61 18-03-14
More insiders
Date Price Change Volume
24-04-12 12.36 -6.29% 4,500,970
24-04-11 13.19 +4.85% 3,756,314
24-04-10 12.58 -4.84% 5,652,865
24-04-09 13.22 +1.15% 4,225,435
24-04-08 13.07 -3.40% 4,660,426

Delayed Quote Nasdaq, April 12, 2024 at 04:00 pm EDT

More quotes
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
12.36 USD
Average target price
26 USD
Spread / Average Target
+110.36%
Consensus